Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenSight Biologics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018 10
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
GenSight Biologics Raises US$41.6 Million In Series A Financing 13
Partnerships 15
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 15
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 16
GenSight Biologics Enters into Research Agreement with Friedrich Miescher Institute 17
GenSight Biologics Enters into Agreement with Genethon 18
Licensing Agreements 19
Gensight Biologics Exercises its Option Agreement with Massachusetts Institute of Technology 19
GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech 20
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 22
GenSight Biologics Enters into Licensing Agreement with Novartis Pharma 24
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 25
Equity Offering 27
Gensight Biologics Raises USD25 Million in Private Placement of Shares 27
GenSight Biologics Announces Underwriters Exercise of Partial Over-Allotment Option for IPO of Shares for USD50.5 Million 28
GenSight Biologics Raises USD35.3 Million in Private Placement of Series B Preferred Stock 30
GenSight Biologics SA – Key Competitors 32
GenSight Biologics SA – Key Employees 33
GenSight Biologics SA – Locations And Subsidiaries 34
Head Office 34
Recent Developments 35
Financial Announcements 35
Jul 25, 2018: GenSight Biologics Reports Interim Financial Results for the First Half of 2018 35
Jan 25, 2018: GenSight Biologics Reports €55 Million 2017 Year-End Cash Position and Provides Corporate Update 36
Jul 28, 2017: GenSight Biologics Reports Interim Financial Results for the First Half of 2017 37
Apr 26, 2017: GenSight Biologics Reports Its Cash Position as of March 31, 2017 38
Mar 13, 2017: GenSight Biologics Reports Full Year 2016 Financial Results 39
Corporate Communications 40
Oct 25, 2017: GenSight Biologics Appoints Barrett Katz as Chief Medical Officer 40
Oct 02, 2017: GenSight Biologics Integrates the Enternext PEA-PME 150 Index 41
May 03, 2017: Gensight Biologics Appoints Mohamed Genead as Chief Medical Officer 42
Product News 43
10/16/2017: GenSight Biologics to Present Data on GS010 at 2017 Congress of the European Society of Gene & Cell Therapy 43
10/16/2017: GenSight Biologics to Present Data on GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy 44
06/14/2017: GenSight Biologics Reports Long-Term Positive Safety and Visual Acuity Results at Week 96 in Phase I/II Study of GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy 45
05/08/2017: GenSight Biologics to Present Data on GS030 at the Annual Meeting of ARVO 46
Product Approvals 47
Jan 31, 2017: GenSight Biologics Receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa 47
Clinical Trials 48
Jun 20, 2018: GenSight Biologics : Key Opinion Leaders Highlight GS010 Efficacy and Patient Benefits in Discussion of Findings from REVERSE Phase III Clinical Trial 48
Jun 12, 2018: GenSight Biologics Reports Positive Additional Data from REVERSE Phase III Clinical Trial of GS010 for Treatment of Leber Hereditary Optic Neuropathy (LHON) 50
Apr 26, 2018: GenSight Biologics to Present Data on GS010 at the Annual Meeting of Association for Research in Vision and Ophthalmology 52
Apr 03, 2018: GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON) 54
Feb 20, 2018: GenSight Biologics Announces Publication of Positive Data from Phase I/II Trial and Long-Term Follow-up of GS010 in Ophthalmology, the Journal of the American Academy of Ophthalmology 56
Dec 05, 2017: GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) 58
Aug 01, 2017: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the Treatment of Leber’s Hereditary Optic Neuropathy 60
May 08, 2017: GenSight Biologics to Present Data on GS010 at the Annual Meeting of ARVO 61
Feb 21, 2017: GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy 62
Other Significant Developments 63
Apr 25, 2018: GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
GenSight Biologics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenSight Biologics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenSight Biologics SA, Deals By Therapy Area, 2012 to YTD 2018 9
GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018 10
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GenSight Biologics Raises US$41.6 Million In Series A Financing 13
GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS 15
GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS 16
GenSight Biologics Enters into Research Agreement with Friedrich Miescher Institute 17
GenSight Biologics Enters into Agreement with Genethon 18
Gensight Biologics Exercises its Option Agreement with Massachusetts Institute of Technology 19
GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech 20
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 22
GenSight Biologics Enters into Licensing Agreement with Novartis Pharma 24
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 25
Gensight Biologics Raises USD25 Million in Private Placement of Shares 27
GenSight Biologics Announces Underwriters Exercise of Partial Over-Allotment Option for IPO of Shares for USD50.5 Million 28
GenSight Biologics Raises USD35.3 Million in Private Placement of Series B Preferred Stock 30
GenSight Biologics SA, Key Competitors 32
GenSight Biologics SA, Key Employees 33
List of Figures
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018 10
